Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.85 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.66 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7113122 | 0.92 | ALDH1A1 (1.00) | ALDH1A1POLBSMN1; SMN2SGMS1PKM | |
| SCHEMBL25138688 | 0.92 | ALDH1A1 (0.85) | ALDH1A1POLBSMN1; SMN2SGMS1PKM | |
| SCHEMBL8779503 | 0.90 | ALDH1A1 (0.82) | ALDH1A1POLBSMN1; SMN2SGMS1PKM | |
| SCHEMBL11335294 | 0.87 | ALDH1A1 (0.88) | ALDH1A1POLBSMN1; SMN2SGMS1PKM | |
| SCHEMBL15619063 | 0.87 | ALDH1A1 (0.88) | ALDH1A1POLBSMN1; SMN2PKMAKR1C3 | |
| SCHEMBL5188475 | 0.85 | ALDH1A1 (0.81) | ALDH1A1POLBSMN1; SMN2SGMS1PKM | |
| SCHEMBL10523408 | 0.85 | ALDH1A1 (0.86) | ALDH1A1POLBSMN1; SMN2SGMS1PKM | |
| SCHEMBL29259801 | 0.85 | ALDH1A1 (1.00) | ALDH1A1POLBSMN1; SMN2PKMTAAR1 | |
| SCHEMBL29259796 | 0.85 | ALDH1A1 (0.86) | ALDH1A1POLBSMN1; SMN2SGMS1PKM | |
| SCHEMBL6799293 | 0.85 | ALDH1A1 (0.86) | ALDH1A1POLBSMN1; SMN2SGMS1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10195167-B2 | Compounds for use in the treatment of conditions associated with NADPH oxidase | GLUCOX BIOTECH AB (SE) | 2019-02-05 | — | — | US | claimed |
| US-20180271810-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | GLUCOX BIOTECH AB (SE) | 2018-09-27 | — | — | US | claimed |
| EP-3233072-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | Glucox Biotech AB (SE) | 2017-10-25 | — | — | EP | claimed |
| WO-2016096720-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | GLUCOX BIOTECH AB (SE) | 2016-06-23 | — | — | WO | claimed |
| US-10195167-B2 | Compounds for use in the treatment of conditions associated with NADPH oxidase | GLUCOX BIOTECH AB (SE) | 2019-02-05 | — | — | US | disclosed |
| US-10195167-B2 | Compounds for use in the treatment of conditions associated with NADPH oxidase | GLUCOX BIOTECH AB (SE) | 2019-02-05 | — | — | US | disclosed |
| US-20180271810-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | GLUCOX BIOTECH AB (SE) | 2018-09-27 | — | — | US | disclosed |
| EP-3233072-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | Glucox Biotech AB (SE) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016096720-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | GLUCOX BIOTECH AB (SE) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016096720-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | GLUCOX BIOTECH AB (SE) | 2016-06-23 | — | — | WO | disclosed |
| US-20030191309-A1 | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production | HO WEN-BIN (US) | 2003-10-09 | — | — | US | disclosed |
| US-6506936-B1 | Treating fibrotic disorder selected from hepatic cirrhosis and arthritis; inhibiting matrix metalloproteases | FIBROGEN, INC. | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191309-A1 | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production | MMP1, MMP13, COL14A1 | ALDH1A1 1188/4885POLB 3593/4885SMN1; SMN2 3122/4885 |
| US-20180271810-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | CYBB, NOX4, NOX1 | ALDH1A1 195/4885POLB 786/4885SMN1; SMN2 444/4885 |
| US-10195167-B2 | Compounds for use in the treatment of conditions associated with NADPH oxidase | CYBB, NOX4, NOX1 | ALDH1A1 195/4885POLB 786/4885SMN1; SMN2 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.